Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gregory Gullo

Interventional Pain Medicine West Linn, OR Medical Doctor

NPI 1124075791 CMS profile 96832

2020 8Th Ave, Suite 200, West Linn, OR 97068

Open in the dashboard

General payments

$4,494

163 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gregory Gullo of West Linn, OR is reported in the CMS Open Payments database as having received $4,494 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $15 1
2022 General $250 9
2021 General $502 16
2020 General $2,044 45
2019 General $1,683 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Gullo
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Gregory Gullo were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Gregory Gullo Interventional Pain Medicine median Middle half National median
2019 $1,683 $684 $216–$2,079 $163
2020 $2,044 $382 $122–$1,109 $114
2021 $502 $552 $167–$1,554 $132
2022 $250 $605 $187–$1,924 $149
2023 $15 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $1,207 16 payments
  2. VGI Medical, LLC $445 1 payment
  3. Pfizer Inc. $293 20 payments
  4. Daiichi Sankyo Inc. $290 30 payments
  5. Nevro Corp. $255 3 payments
  6. Lilly USA, LLC $254 11 payments
  7. Allergan Inc. $221 11 payments
  8. Biodelivery Sciences International, Inc. $180 8 payments
  9. GRT US Holding, Inc. $135 2 payments
  10. Medtronic USA, Inc. $130 3 payments
  11. Other $1,083 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,185 158 payments
  2. Travel and Lodging $864 4 payments
  3. Entertainment $445 1 payment
Products named General payments · program years 2019–2023
  1. Proclaim Family of SCS IPGs $810 11 payments
  2. SiJoin $445 1 payment
  3. Morphabond ER $290 30 payments
  4. Neuromodulation Dspsbls and Accs $257 2 payments
  5. Senza Spinal Cord Stimulation System $255 3 payments
  6. LYRICA $253 18 payments
  7. EMBEDA $186 12 payments
  8. UBRELVY $184 9 payments
  9. FLECTOR PATCH $165 11 payments
  10. AIMOVIG $137 7 payments
  11. Other $2,296 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record